Noida, May 13 (APAC Media): Pharma major Cipla, on Wednesday, reported a 54% year-on-year decline in consolidated net profit to Rs 555 crore for the quarter ended March (Q4 FY26), compared with Rs 1,222 crore in the same period last year, according to a regulatory filing.
The company’s EBITDA declined 35% year-on-year to Rs 997 crore, compared with Rs 1,538 crore in the corresponding period last year.
Income from operations stood at Rs 6,541 crore in Q4 FY26.
The Board of Directors of the company, at its meeting held on May 13, 2026, has recommended a final dividend of Rs 13 per equity share (face value Rs 2 each) for the financial year ended March 31, 2026, subject to approval of shareholders at the ensuing annual general meeting.
“I am pleased to share that we continue to make considerable progress across our focused markets. In FY26, we recorded our highest-ever yearly revenue of INR 28,163 cr, reflecting the strength of our core businesses despite near-term challenges in certain markets. Our One-India business crossed the INR 12,500 Cr milestone, with strong performance across Branded Prescription, Trade Generics, and Consumer Health businesses,” said Achin Gupta, MD and Global CEO, Cipla Ltd.
One-India’s business grew 15% year-on-year, with all three segments delivering double-digit growth during the quarter, driven by continued momentum in branded prescription therapies, steady expansion in trade generics, and sustained growth in consumer health anchor brands.
“Looking ahead, we will focus on growing key markets, strengthening flagship brands, investing in the future pipeline, and advancing regulatory resolutions across geographies, while sustaining momentum in the US, Africa, emerging markets, and Europe,” Achin added.
In North America, the company posted quarterly revenue of $155 million, supported by demand for its differentiated portfolio and a stable base business.
The One Africa region reported strong growth momentum, with revenue rising 14% year-on-year in USD terms, while Emerging Markets and Europe (EMEU) recorded revenue of $90 million despite geopolitical uncertainties.
R&D expenditure stood at Rs 509 crore, or 7.8% of sales for the quarter, driven by ongoing product filings and development initiatives.
The company also reported a strong net cash position of Rs 10,526 crore, with debt primarily comprising lease liabilities and working capital requirements.
Disclaimer: Views expressed are those of experts and do not reflect APAC Media. This is for informational purposes only, not financial advice. We are not responsible for investment decisions. Please consult a qualified financial advisor before investing.
Also Read:
HPCL Q4 Results: Cons Net Profit Skyrocket 78% YoY to Rs 6,065 Crore; Announces Rs 19.25 Dividend
Discussion about this post